Preprint finds gray-market retatrutide users lose less weight than trial participants

The wire

1. 01A preprint reported that people using compounded, gray-market retatrutide, an investigational triple agonist, achieved less weight loss over up to 12 months than participants in clinical trials of the drug.
2. 02Telehealth operators and clinicians fielding questions about unapproved retatrutide now have a data point on real-world results from product of unverified content and dosing.
3. 03The study is a preprint and not peer reviewed; the roundup also flags Novo Nordisk's phase III OASIS 5 test of lower oral semaglutide doses and reports of sanitation workers pricked by discarded GLP-1 pens.

From the source

'Gray Market' Retatrutide Study; Menopause and the Brain; Drug Allergy Warnings

— News and commentary from the endocrinology world